Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. It develops product candidates for the treatment of Parkinson’s disease and cognition. The Company’s product pipeline includes ND0612L, for moderate PD; ND0612H, for severe PD; ND0680, for severe PD; ND0701, for severe PD, and ND0801, for Cognitive Disorders. It developed a liquid formulation of levodopa (LD) and carbidopa (CD). The Company developed a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. Its LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson’s disease.